← Back to all trials
Recruiting
NCT07499232
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Conditions: Crohn Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 530
Sponsor: Janssen Research & Development, LLC
Location: Digestive Health Specialists of the Southeast Dothan Alabama
Summary
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Eligibility Criteria
Inclusion criteria:
* Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy
* Have moderately to severely active CD, defined as baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\>=) 220 but less than or equal to (\
Source: ClinicalTrials.gov (NCT07499232). StuddyBuddy aggregates publicly available trial information.
